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Gram- negative bacteria utilize a diverse array of multidrug transporters to pump toxic
compounds out of the cell. Some transporters, together with periplasmic membrane
fusion proteins (MFPs) and outer membrane channels, assemble trans-envelope
complexes that expel multiple antibiotics across outer membranes of Gram-negative
bacteria and into the external medium. Others further potentiate this efflux by pumping
drugs across the inner membrane into the periplasm. Together these transporters create
a powerful network of efflux that protects bacteria against a broad range of antimicrobial
agents. This review is focused on the mechanism of coupling transport reactions located in
two different membranes of Gram-negative bacteria. Using a combination of biochemical,
genetic and biophysical approaches we have reconstructed the sequence of events leading
to the assembly of trans-envelope drug efflux complexes and characterized the roles of
periplasmic and outer membrane proteins in this process. Our recent data suggest a
critical step in the activation of intermembrane efflux pumps, which is controlled by MFPs.
We propose that the reaction cycles of transporters are tightly coupled to the assembly
of the trans-envelope complexes. Transporters and MFPs exist in the inner membrane as
dormant complexes. The activation of complexes is triggered by MFP binding to the outer
membrane channel, which leads to a conformational change in the membrane proximal
domain of MFP needed for stimulation of transporters. The activated MFP-transporter
complex engages the outer membrane channel to expel substrates across the outer
membrane. The recruitment of the channel is likely triggered by binding of effectors
(substrates) to MFP or MFP-transporter complexes. This model together with recent
structural and functional advances in the field of drug efflux provides a fairly detailed
understanding of the mechanism of drug efflux across the two membranes.
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TRANSPORTERS
Multidrug resistance or polyspecific transporters (MDRs) are
present in all living systems. However, they are particularly abun-
dant and diverse in bacteria and comprise 2–7% of the total
bacterial protein content (Saier and Paulsen, 2001). Such putative
MDRs are identified based on sequence similarity with exper-
imentally confirmed transporters able to handle multiple sub-
strates. Most of these substrates are hydrophobic or amphipathic
molecules often containing weakly basic moieties. Other sub-
strates are organic cations with a permanent charge distributed
over a large hydrophobic surface (Hall et al., 1998; Zgurskaya and
Nikaido, 2000b).
Functional studies and subsequent phylogenetic analysis
demonstrated that bacterial MDR transporters can be organized
into several evolutionary distinct protein families that signifi-
cantly differ in bioenergetics, structure and transport mechanism
(Saier and Paulsen, 2001). Most of MDRs are found in three large
and diverse superfamilies: ABC (ATP-binding Cassette) (Higgins
and Linton, 2004), MF (Major Facilitator) (Saier et al., 1999)
and RND (Resistance-Nodulation-Cell Division) (Tseng et al.,
1999). In addition, some MDRs form a core of smaller super-
families: SMR (Small Multidrug Resistance) family [now part of
the DMT (Drug/metabolite Transporter) superfamily] (Chung
and Saier, 2001) and MATE (Multidrug and Toxic Extrusion)
family [recently joined the MOP (Multidrug/Oligosaccharidyl-
lipid/Polysaccharide) superfamily] (Hvorup et al., 2003). Just
recently, a new family of transporters involved in efflux of cyclo-
hexidine has been identified in Acinetobacter spp. (Hassan et al.,
2013).
ABC MDRs (as all other members of this superfamily) are
primary active transporters which couple substrate transloca-
tion with binding and hydrolysis of ATP. MDRs in all the other
superfamilies are secondary transporters which utilize electro-
chemical gradients of ions (most frequently protons but some-
times sodium) to transport their diverse substrates. Both primary
and secondary transporters are ubiquitous in bacteria, however
their relative presence seems to correlate with energy genera-
tion: fermentative bacteria tend to rely more on the primary
transporters while genomes of aerobic bacteria contain somewhat
more secondary transporters (Paulsen et al., 1998, 2000).
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EFFLUX ACROSS CYTOPLASMIC MEMBRANES
At least three steps are common to various transporters dur-
ing transport across cytoplasmic membranes: (i) binding of a
substrate on the cytoplasmic or periplasmic side of the mem-
brane, (ii) conformational changes in a transporter leading to
re-orientation of the binding site to the other side of the mem-
brane, and (iii) the release of the substrate. The conformational
change leading to reorientation of substrate binding sites and
relaxation of a transporter are usually energy-dependent steps,
which is provided by either ATP hydrolysis (ABC pumps) or
by a proton motive force (PMF) or sodium motive force. The
basic mechanism of energization of transporters by ATP and PMF
are well understood on examples of ABC and MF transporters
(Davidson et al., 2008; Fluman and Bibi, 2009) but require fur-
ther analyses in other transporters such as those belonging to the
RND superfamily (Eicher et al., 2014).
The directionality of the transport is defined by binding affin-
ity on either side of the membrane and the transport reaction is
thought to be reversible at least in the case of PMF-dependent
pumps (Smirnova et al., 2011; Fluman et al., 2012). However,
RND pumps seem to be uni-directional with some of them trans-
porting substrates only across the outer membrane (Nikaido and
Pages, 2012). In these transporters, the substrate binding site is
located in the periplasmic domain and is separated from the pro-
ton translocation pathway. Other RND pumps, such as the metal
efflux pump CusBAC from E. coli, transport substrates across
both the cytoplasmic and the outer membranes. This transporter
comprises a network of methionine and charged residues travers-
ing the transmembrane and periplasmic domains and involved in
metal binding and transport (Su et al., 2011, 2012).
Transporters belonging to the same family of proteins are
capable of efflux either alone or in complexes with accessory
proteins. Mechanisms of transporters that function in com-
plexes with other proteins are likely to be very similar to single-
component ones. Studies of various transporters suggested that
accessory proteins located in the periplasm and in the outer mem-
brane enable high affinities toward substrates and also couple
transport reactions separated in two different membranes.
EFFLUX ACROSS OUTER MEMBRANES
Efflux is most effective when working in cooperation with other
resistance mechanisms. Reduced uptake across the outer mem-
brane of Gram-negative bacteria, which is a significant perme-
ability barrier for both hydrophilic and hydrophobic compounds,
constitutes such a mechanism (Sen et al., 1988; Sanchez et al.,
1997). To take advantage of the reduced uptake, some Gram-
negative MDR pumps extrude their substrates across the outer
membrane directly into the external medium.
Permeability constants of amphiphilic antibiotics across cyto-
plasmic and outer membranes often differ by several orders of
magnitude. Therefore, efflux is most effective when antibiotics
are transported across the outer membrane back into the external
medium. Among various MDRs, some transporters belonging to
RND, ABC, andMF superfamilies utilize energy conserved in ATP
or in the PMF of the cytoplasmic membrane to transport drugs
across the outer membrane, which is energy deficient. This trans-
duction of energy is possible because of the association between
the transporters and two types of accessory proteins: the periplas-
mic Membrane Fusion Proteins (MFP) and the outer membrane
channels (OMFs) (Paulsen et al., 1997).
Importantly, the trans-envelope efflux of antibiotics con-
tributes to resistance in clinical settings. In clinical Escherichia
coli andKlebsiella pneumoniae isolates, fluoroquinolone resistance
is linked to overproduction of AcrAB efflux pump, and mul-
tiple efflux pumps, including MexAB-OprM, confer antibiotic
resistance in Pseudomonas aeruginosa (Ziha-Zarifi et al., 1999;
Padilla et al., 2010; Swick et al., 2011). Also in P. aeruginosa,
elevated expression of MexXY is the major cause of aminoglyco-
side resistance in the absence of modifying enzymes (Poole and
Srikumar, 2001). The unquestionably significant impact of mul-
tidrug efflux pumps on the effectiveness of antibiotics in clinical
settings makes them attractive targets for inhibition (Lomovskaya
et al., 2008a,b). This review is focused on the mechanism of
coupling drug transport reactions in the cytoplasmic and outer
membranes. This critical step in drug efflux could be targeted for
development of effective inhibitors of efflux pumps.
OUTER MEMBRANE CHANNELS
The outer membrane of Gram-negative bacteria is an asymmet-
ric lipid bilayer, which significantly slows down diffusion of drugs
and bile salts into the cell. Although the inner leaflet of the outer
membrane is composed of glycerophospholipids, the major com-
ponents of cytoplasmic membranes, the outer leaflet is composed
of lipopolysaccharides (LPS) which are largely responsible for
the low permeability characteristic (Tommassen, 2010; Gessmann
et al., 2014). Of the five existing families of Gram-negative outer
membrane channels (Hagan et al., 2011), only proteins belong-
ing to the Outer Membrane Factor (OMF) family associate with
periplasmicMFPs and active transporters to drive the extrusion of
ions, drugs, peptides and other substrates across the outer mem-
brane (Yen et al., 2002). During transport, OMFs are believed
to transition between the “open” and “closed” conformational
states. In the resting state, the channel is in the “closed” confor-
mation and is not permeable to most of its substrates. Induction
of the conformational changes necessary to “open” the periplas-
mic aperture of OMFs is credited to theMFPs, which also stabilize
the trans-envelope protein complexes and enable export of vari-
ous substrates through OMFs (Matias et al., 2003; Lobedanz et al.,
2007; Tikhonova et al., 2009).
OMF STRUCTURE
Similar to other outer membrane proteins, OMFs have a signa-
ture β-barrel domain but these proteins also have unique features
befitting their functions in the trans-envelope transport. The
first OMF purified and characterized was the homotrimeric TolC
from E. coli that functions with various drug efflux pumps of
RND (e.g., AcrAB), ABC (e.g., MacAB) and MF (e.g., EmrAB)
superfamilies (Figure 1) (Koronakis et al., 2000). TolC is a 12 β-
strand barrel, which is 30 Å wide and contains six asymmetric
loops exposed to the cell surface. The β-barrel extends into the
periplasm as an α-barrel of 140 Å long. The α-barrel is formed by
12 α-helices—six continuous and six discontinuous—that share
similar sequences and inter-helical interactions, yet one pair of
helices is inclined by−20◦ with respect to the molecular threefold
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FIGURE 1 | The Structure of Homotrimeric TolC. (A) Crystal structure of
TolC (PDB code—1EK9). The individual protomers are colored. The
β-barrel and extracellular loops are 40 Å long while the α-barrel is 140 Å
deep into the periplasm. (B) A trace of an individual TolC protomer. The
β-barrel domain is in light blue, the α-helical barrel in blue, and the
equatorial domain in dark blue. (C) Crystal structure highlighting the open
cavity of the TolC channel. (D) The “closed” resting state of the TolC
periplasmic aperture.
axis. The introduced curvature yields a “closed” aperture of the
periplasmic end of TolC. The α-barrel domain is belted by an α/β
structure that comprises the equatorial domain.
TolC homologs crystallized since then, MtrE, VceC, OprM,
and CusC, conserve closely the α- and β-barrel architecture
(Akama et al., 2004a; Federici et al., 2005; Kulathila et al., 2011; Lei
et al., 2014). The equatorial domain is also retained but with sig-
nificant variation, particularly in the C terminus (Federici et al.,
2005; Kulathila et al., 2011). Highlighting the important role of
the equatorial domain, mutations in the N and C termini atten-
uate the function of TolC (Yamanaka et al., 2002, 2004; Bokma
et al., 2006; Krishnamoorthy et al., 2013).
Most of the available structures of OMFs, including TolC,
OprM and CusC are closed at one or both sides. Several structures
of the TolC variants, in which the opening of the TolC exit duct
was forced by removal of key interactions, have been reported
(Andersen et al., 2002; Bavro et al., 2008; Pei et al., 2011). A
network of inter- and intra-protomer bonds that constrains the
inner and outer coiled coils in their closed conformation is cen-
tered at four key residues: Thr152, Asp153, Tyr362, and Arg367.
Disruption of key hydrogen bonds and salt bridges involving these
residues allowed movement of the inner coiled coils and widened
the periplasmic pore (Andersen et al., 2002). Structural charac-
terization of these TolC mutants presented sequential snapshots
of both symmetrical and asymmetrical openings of the entrance
aperture, revealing that relaxation of the constraining network
allows both a twist and dilation at the entrance (Bavro et al., 2008;
Pei et al., 2011). These studies also suggested that interactions
with transporters and periplasmic proteins are likely to contribute
significantly to opening of the channel.
Surprisingly, the crystal structure of MtrE showed that this
channel is open all the way from the outer membrane surface and
down to the tip of the α-helical periplasmic domain (Figure 2)
(Lei et al., 2014). The widest section of the channel is located
at the external surface of the outer membrane, with the inter-
nal diameter of ∼22 Å. Hence, MtrE could be a highly dynamic
channel spontaneously transitioning between the closed and open
states. Like TolC and other OMFs, MtrE also contains an aspar-
tate ring at its periplasmic entrance. Each protomer of MtrE
contributes Asp402 and Asp405 to form two concentric circles
of negative charges in the inner cavity of MtrE, which could
contribute to the selectivity of the channel (Figure 2).
PROPOSED MECHANISM
The structural and functional studies suggested that open-
ing of the channel could be achieved by interrupting inter-
and intramolecular interactions that stabilize the resting state.
Interactions with both a transporter and a MFP were considered
as driving forces for OMF transition into the open state.
The E. coli K-12 periplasm is estimated to range ∼18–23 nm
(Matias et al., 2003). In case of RND-containing complexes, the
periplasmic portion of the AcrB transporter is large enough to
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FIGURE 2 | The Structure ofNeisseria gonorrhoeaeMtrE. (A) Bottom view
of the open conformational state of MtrE (generated by SWISS-MODEL)
compared to TolC (bottom). The narrowest region of MtrE tunnel is ∼12 Å. (B)
Acidic residues of the α-helical barrel ofMtrE contribute to substrate selectivity.
(C) A unique feature at the MtrE periplasmic opening—two negatively charged
concentric rings composed by Asp402 (blue) and Asp405 (green).
reach halfway across the periplasm and contact TolC directly
(Murakami et al., 2002). If AcrB and TolC structures are docked in
a tip-to-tip manner the complex spans ∼17 nm of the periplasm
and the drug exit funnel of AcrB is sealed by the periplasmic
duct of TolC preventing the escape of substrates into periplasm
(Murakami et al., 2002; Symmons et al., 2009). This model
has found a support at both the genetic and biochemical lev-
els. Binding experiments showed that the transporter-channel
AcrB-TolC pair forms a highly dynamic complex, even in the
absence of MFP AcrA (Tikhonova et al., 2011). An “open” TolC
variant containing Tyr362 to Phe and Arg367 to Glu substi-
tutions (TolCYFRE) showed significantly lower affinity to AcrB
(Tikhonova et al., 2011), suggesting that opening of the chan-
nel could lead to destabilization of interactions, disengagement
of the complex and channel closing. The proposed AcrB-TolC
interface is formed by AcrB β-hairpins extending from its TolC-
docking domain. Genetic studies showed that these hairpins play
an important role in the functional assembly of the pump com-
plex by stabilizing interactions with TolC (Weeks et al., 2014).
However such a limited interface could initiate the opening of the
channel but is not sufficient to release interactions that keep the
channel in its closed state (Weeks et al., 2010). Interestingly, in the
assembled tri-partite AcrAB-TolC complex, AcrB and TolC do not
contact each other (Du et al., 2014). Also, transporters belonging
to ABC and MF superfamilies of proteins lack the large periplas-
mic domains of AcrB and do not interact with OMF directly
(Lu and Zgurskaya, 2013). Hence the transporter-channel inter-
face, if formed, is not a requirement for assembling a functional
complex. This function is assigned to MFPs that play a critical
role in coupling transport reactions separated in two different
membranes.
COUPLING OF TWOMEMBRANES: PERIPLASMIC
MEMBRANE FUSION PROTEINS
MFPs play an important functional role in trans-envelope drug
efflux: (i) by stimulating the efflux activities of transporters and
(ii) by engaging OMFs and opening them for substrates to be
expelled from the cell (Zgurskaya et al., 2009). In vitro recon-
stitution studies showed that the stimulating activities of MFP
are a common feature of transporters belonging to various pro-
tein families. E. coli AcrA, that functions with the RND pump
AcrB, and MacA, a subunit of the ABC-type MacB transporter,
both stimulate activities of their cognate transporters located in
the inner membrane (Zgurskaya and Nikaido, 1999b; Tikhonova
et al., 2007). On the other hand, MFPs mediate and stabilize
the functional interactions between transporters and OMFs and
in doing so, presumably transmit energy from the energized
transporter to the closed OMF in order to open the channel
and allow the diffusion of substrates through the OMF into
the extracellular medium. It is thought that this transfer of
energy is mediated by conformational energy and movement of
the MFPs.
STRUCTURE OF MFPs
While amino acid conservation among MFPs is relatively low,
their structures are conserved. Typical MFPs are highly elongated
proteins, and adopt a linear conformation that extends from the
outer leaflet of the inner membrane deep into the periplasm to
meet the OMF (Zgurskaya and Nikaido, 1999a; Mikolosko et al.,
2006). This linear structure comprises up into four characteris-
tic domains. Starting at the inner membrane, the domains are the
membrane proximal (MP), β-barrel, lipoyl, and α-helical hairpin
domains (Figure 3). While these domains are arranged in a linear
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FIGURE 3 | Schematic organization of Membrane Fusion Proteins.
(A) Typical membrane fusion proteins (MFPs) contain four domains
which are broken and distributed between the N- and C-halves of the
protein. As MFPs are periplasmic proteins, they contain an N-terminal
transmembrane segment (TMS) or signal peptide (SP). The N-terminal
half of the protein encodes for a small portion of the membrane
proximal (MP) and β-barrel domains (BB), half of the lipoyl domain and
one of the α-helices of the α-helical domain. The C-terminal half
encodes for the second α-helix, the second half of the lipoyl domain
and the majority of the BB and MP domains. (B) When folded, MFPs
form an elongated structure with four unique domains. From the inner
membrane, the domains are organized as MP, BB, lipoyl and α-helical.
The domains are separated by short flexible linkers. Due to the flexibility
of these linker regions, MFPs are capable of dramatic variation in
structure, likely to allow for conformational changes which transmit
energy from the IMP to the OMF. The MP, BB, and lipoyl domains are
primarily comprised of β-sheets, while the α-helical domain is typically a
single pair of anti-parallel α-helices connected by a single turn.
manner, the N-terminal and C-terminal halves of the protein fold
in upon each other to complete the structure.
The MP, β-barrel and the lipoyl domains are mostly β-
sheet structures. The α-hairpin domain, unlike the other three
domains, consists of two anti-parallel coiled-coils separated by
a single turn. The domains are linked by flexible unstructured
regions which give the overall protein its conformational flex-
ibility and allow for a high degree of movement believed to
be important for functional interactions with transporters and
OMFs.
The α-helical hairpins oligomerize and assemble a funnel-like
structure that interacts with an OMF. The MP, β-barrel, and pos-
sibly the lipoyl domain are responsible for interactions with the
cognate transporter. In addition, someMFPs, such as MacA, con-
tain N-terminal transmembrane domains (TMD) that interact
with transporters within the cytoplasmic membrane (Tikhonova
et al., 2007). However, in many other MFPs this TMD is replaced
by a lipid modification that anchors the protein into the mem-
brane. As the different families of transporters vary in sizes of
domains exposed to the periplasm, MFPs and their domains
which interact with specific transporters also vary. For exam-
ple, MF transporters such as E. coli EmrB are thought to have
little to no periplasmic extrusions (Figure 4). Accordingly, its
cognate MFP, EmrA, lacks a MP domain and contains a very
long α-hairpin sufficient to span the periplasm and bind TolC
(Hinchliffe et al., 2014). On the other side of the MFP diver-
sity spectrum is BesA, the MFP of Borrelia burgdorferi BesABC
complex, which lacks an α-hairpin domain all together (Greene
et al., 2013). The exact reasons for the lack of the α-hairpin
remains unclear, but it could be due to the fact that OMF,
BesC, lacks the aspartate ring in the periplasmic duct of the
channel suggesting that MFP binding to the periplasmic tip
of BesA could be sufficient to trigger opening of the channel
(Bunikis et al., 2008).
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FIGURE 4 | Structures of divergent MFPs. Crystal structures of MexA,
BesA, and EmrA are shown to show structural variation of MFPs (PDB
accession numbers 2V4D, 4KKS, and 4TKO, respectively). The typical MFP
is exemplified by the structure of MexA, which contains all four of the
typical domains. BesA is the MFP of the BesABC RND efflux complex of B.
burgdorferi. The OMF, BesC, does not contain both of the ionic gates which
keep the periplasmic aperture in a closed position. Due to this lack of
additional gating, it is thought that BesA no longer needs the α-helices
because of the weakened gating of the aperture. Conversely, EmrA
interacts with the MFS transporter EmrB. EmrB contains little to no
periplasmic domain for EmrA to interact with. It is thought that EmrA
interacts with EmrB primarily through the N-terminal transmembrane
segment which anchors EmrA to the membrane and not through the MP
domain. Due to the loss of the MP domain in EmrA, the α-helical domain
has been extended. This extended α-helical domain allows for EmrAB to
interact properly with TolC so as to allow efflux of substrates into the
extracellular space.
INTERACTIONS BETWEEN MFPs AND OTHER COMPLEX COMPONENTS
Oligomerization of MFPs
MFPs oligomerize independently of interactions with their cog-
nate IMPs and OMFs. The first evidence of MFP oligomeriza-
tion came from in vivo cross-linking studies of AcrA and HlyD
(Thanabalu et al., 1998; Zgurskaya and Nikaido, 2000a). More
recently, structural studies showed that in crystals MFPs such as
P. aeruginosa MexA and E. coli MacA, and AcrA, all have repeat-
ing dimer pairs (Akama et al., 2004b; Mikolosko et al., 2006; Yum
et al., 2009). AcrA is a dimer of dimers, MacA forms a hexameric
funnel-like structure, whereas MexA has sets of dimers aligned
with one another creating a sheet, which wraps upon itself in
an asymmetric fashion. These structures suggested that the MFPs
could function as dimers, but the strongest evidence for a dimer
as a functional unit of MFPs was collected by biochemical and
genetic studies (Mima et al., 2007; Tikhonova et al., 2009, 2011;
Xu et al., 2011a).
For MFPs which interact with RND transporters (e.g., MexA
and AcrA), the MFP oligomerization was treated more as an
artifact of crystallization, partly due to the fact that hydrody-
namic studies and the size exclusion chromatography studies
showed only monomers in solution (Zgurskaya and Nikaido,
1999a; Tikhonova et al., 2009). However, kinetic studies estab-
lished that MFPs that function with transporters belonging to
different protein families all oligomerize, albeit to a different
degree (Tikhonova et al., 2009). EmrA and MacA, MFPs func-
tioning with MFS and ABC transporters, respectively, form more
stable oligomers and with a higher affinity than AcrA. This result
suggested that interactions with the periplasmic domains of AcrB
stabilize the oligomeric state of AcrA. In contrast, MFPs that func-
tion with transporters lacking large periplasmic domains have a
strong propensity to self-oligomerization. These studies suggested
that oligomerization of MFPs is needed to seal the gap between
their cognate transporters and TolC.
Further in vivo (construction of genetic fusions, Xu et al.,
2011a) and in vitro (binding affinities of stabilized dimers
Tikhonova et al., 2011) studies showed that the functional unit
of MFPs is a dimer, which assembles into a trimer of dimers
when in the complex. Perhaps the most natural evidence of
MFP dimers, as functional units, is the P. aeruginosa triclosan-
specific TriABC-OpmH complex. Mima et al. (2007) identified
this complex through a screen for increasing triclosan resistance
and discovered that TriA and TriB are unique MFPs which are
both required for functionality of the complex.
Interactions between MFPs and transporters
Physical interactions between MFPs and transporters remain
a subject of intense investigation using such approaches as
crystallography, mutagenesis, surface plasmon resonance, iso-
thermal calorimetry, chemical crosslinking, co-purification, and
chimeric protein studies (Weeks et al., 2010, 2014; Su et al., 2011;
Tikhonova et al., 2011; Xu et al., 2011a,b). Symmons et al. (2009)
proposed the first model of AcrAB-TolC complex based on crystal
structures of individual components, in vivo chemical crosslink-
ing and molecular docking analyses. In this model, the AcrA
molecule occupies the AcrB surface between the PN2 and PC2
subdomains, extending up along the DN subdomain. The MP, β-
barrel, and lipoyl domains of AcrA are modeled to interface with
AcrB. Interestingly the PC1 and PC2 cleft of AcrB has been pro-
posed to be one of the main entrance tunnels which substrates use
to enter into the drug binding pocket (Pos, 2009). This further
suggested that MFPs could stimulate activities of their cognate
transporters by participating in drug binding.
In the co-crystal structure of the metal efflux pump CusBA,
the two CusB protomers are positioned substantially higher on
the surface of the CusA transporter than in the cross-linking
based model of AcrAB described above (Symmons et al., 2009;
Su et al., 2011). Here, the MP and β-barrel domains of CusB
interface primarily with the DN and DC subdomains of CusA
and only make limited contacts with the top portions of the PN2,
PC1, and PC2 subdomains. The authors were able to define two
different types of MFP-transporter interactions. The first CusB
molecule primarily engages CusA through an extensive network
of salt bridges. Conversely, the second CusB molecule interacts
with CusA primarily through a network of hydrogen bonding. In
addition, the two CusB are staggered: one of the two molecules
sits slightly higher on the surface of CusA. In this arrangement,
the MP domain of CusB molecule 1 fits into a pocket formed
between the MP and β-barrel domains of molecule 2. When
compared with the cross-linking based model of AcrAB, CusB
molecule 1 is positioned similar to AcrA with the exception that
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the lipoyl domain of CusB does not interface with the transporter
and its MP occupies the position of β-barrel domain of AcrA.
This upward shift also tilts the MFPs and gives them a different
overall structure; CusB has a sickle shape as observed in crys-
tal structures of other MFPs including MacA, AcrA, and MexA.
The recently reported cryo-EM-based structure of the complete
AcrAB-TolC complex shows similar positioning of AcrA on AcrB
transporter (Du et al., 2014). However, only lipoyl domains of
AcrA contribute to AcrA oliomerization and there are no contacts
between the MP domains of AcrA.
In various models of MFP-transporter complexes, at least two
domains of MFP directly contact a transporter: the MP domain
and the β-barrel. Functional importance of these domains in var-
iousMFPs has been supported by genetic and biochemical studies
(Elkins and Nikaido, 2003; Tikhonova et al., 2007; Ge et al., 2009;
Modali and Zgurskaya, 2011). Mutagenesis of the C-terminal
domains of MacA and AcrA identified conserved glycine residues
important for the functional interactions between these MFPs
and the cognate components of the complexes. A substitution of
Gly353 with Cys leads to inactivation ofMacA, and prevents stim-
ulation of the MacB ATPase activity, but not physical interactions
with MacB or TolC (Modali and Zgurskaya, 2011). An analogous
alteration in AcrA, Gly363 to Cys, prevented functional, but not
physical interaction with AcrB and TolC (Ge et al., 2009). Limited
proteolysis studies both in vivo and in vitro showed that these
substitutions affect conformations of the MP domains of AcrA
and MacA. Although EmrA does not have a MP domain, its C-
terminal signature residues of the MFP family of proteins are
incorporated into the β-barrel (Zgurskaya et al., 2009; Hinchliffe
et al., 2014).
Conformational changes and effectors
Early hydrodynamic and EPR studies pointed to significant struc-
tural flexibility of MFPs (Zgurskaya and Nikaido, 1999a; Ip et al.,
2003). In the presence of magnesium ions, the highly asym-
metric shape of AcrA was found to be more compact, whereas
mildly acidic pH restrained significantly conformational dynam-
ics of this protein. The X-ray structure of AcrA suggested that
these conformational changes could involve the α-hairpin, which
undergoes an ∼15◦ rotation between the two most dissimilar
molecules (Mikolosko et al., 2006). In addition, the refined full
structure of MexA showed that the MP domain is also mobile
and that in one of the MexA protomers this domain is twisted
by 85◦ clockwise relative to the β-barrel domain (Symmons et al.,
2009). Additionally, when the lipoyl domains of MexA were
superimposed, the α-hairpins exhibited ∼35◦ of rotation while
the β-barrel and MP domains underwent an additional ∼25◦
of rotation. Molecular dynamics simulations of MexA and AcrA
supported the high inter-domain flexibility of MFPs (Vaccaro
et al., 2006;Wang et al., 2012). In vivo proteolysis studies however,
pointed onto the MP domains of AcrA and MacA that undergo
significant conformational changes and that these changes are
detected only when all three components of complexes are present
and functional (Ge et al., 2009; Modali and Zgurskaya, 2011; Lu
and Zgurskaya, 2012).
The protonation/deprotonation of His285 was proposed to
underlie the pH-regulated conformational dynamics of AcrA by
disturbing the local hydrogen bond interactions (Wang et al.,
2012). Interestingly, in a heavy metal MFP ZneB, the same His
residue is a part of the metal-binding site (De Angelis et al., 2010).
In MacA, the patch of positively charged residues located at the
interface between β-barrel and the MP domains are important
for both binding to core LPS and functionality of the pump,
suggesting that LPS could be a substrate of MacAB-TolC (Lu
and Zgurskaya, 2013). In addition, kinetic experiments showed
that AcrA and other MFPs show differential binding affinities to
OMF and transporters depending on pH (Tikhonova et al., 2009,
2011). Hence, the changes of pH in the periplasm accompany-
ing the drug efflux or binding of substrates/effectors could act as
a signal to trigger the action of MFPs, which undergo reversible
conformational rearrangement.
Several genetic screens with defective complexes were car-
ried out to identify gain-of-function suppressor mutations in
MFPs. Surprisingly, most of such suppressors were mapped to
the β–barrel domains of MFPs, which do not contact OMFs
directly and suppress the defects in complexes through the con-
tact with transporter and long range conformational changes in
the protein. Suppressors of defects in MexB transporter mapped
to the β-barrel domain of MexA were found to increase the sta-
bility of MexA binding to MexB (Nehme and Poole, 2007). An
analogous study of an assembly defective TolC mutant also gave
rise to gain-of-function suppressor mutations within the β-barrel
domain of AcrA (Gerken and Misra, 2004). One such suppres-
sor of the defective TolC mutant was AcrAL222Q, which is itself
labile and subject to degradation if not in a functional complex
with AcrB and TolC (Weeks et al., 2010). It is thought that this
mutant protein is in a conformation which AcrA assumes tran-
siently during typical complex assembly and drug efflux; however,
when locked into this conformation, the protein becomes highly
sensitized to proteolytic degradation by the periplasmic protease
DegP. Other AcrA β-barrel mutants suppressed a TolC mutant
defective in functional interactions with AcrA and AcrB presum-
ably by controlling the opening of TolC channel (Weeks et al.,
2010), or enabled functioning of a hybrid AcrA-MexB-TolC efflux
complex (Krishnamoorthy et al., 2008).
PROPOSED MECHANISM OF TRANS-ENVELOPE DRUG
EFFLUX
Studies discussed above suggest that efflux complexes assembled
with transporters belonging to various protein families utilize the
same mechanism of transport across the outer membrane and
that MFPs play an important role in the functional communica-
tion between transporters and OMF. Although molecular details
of how ABC, MF, and RND transporters bind their substrates and
transport them to the OMFs differ significantly between mem-
bers of different families, all these transporters cycle through three
states that promote access, binding and extrusion of substrates
(Figure 5). The function of MFPs is to couple these transitions
in transporter to opening of OMFs and transport of substrates
across the outer membrane. Most of the investigations were done
on either RND or ABC efflux complexes but it is likely that the
same conclusions apply to MF complexes. The major findings on
the mechanism of MFPs in transport could be summarized in the
following conclusions:
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FIGURE 5 | Proposed mechanism of assembly and trans-envelope
transport by tri-partite efflux pumps. Despite different structures and
mechanisms, RND and ABC transporters cycle through three states that
promote access, binding and extrusion of substrates. In RND transporters,
each protomer cycles through the three conformations. The protomer in the
substrate bound state (blue) is likely to be protonated and its transition into
the extrusion state (red) is coupled to influx of protons. Dimeric ABC
transporters are saturated with ATP, whereas binding of the substrate leads
to transition into a semi-closed (middle panel) conformation. MFPs stabilize
the substrate-bound state of transporters (blue) and drive transporters into
the closed state needed for ATP hydrolysis. Association with TolC drives
conformational changes in the MFP needed for stimulation of transporters.
1. MFP-transporter interactions are sensitive to conformational
changes in transporters. When MacB transporter was trapped
in different conformations by mutations or by the presence of
nucleotide analogs, the affinity of association between MFP
MacA and MacB increased upon ATP binding but remained
unchanged during ATP hydrolysis (Lu and Zgurskaya, 2012).
Similarly, the interactions between the MFP AcrA and the
RND transporter AcrB are most stable when AcrB is in its
protonated state (Janganan et al., 2013). These results sug-
gested that MFPs act on the pre-translocation “Binding” state
of transporters (Figure 5).
2. Stimulation of transporters is coupled to a conformational
change in the C-terminal domain of MFPs. Reconstitution
studies showed that interactions between MFPs and trans-
porters increase the rates of transport and energy consump-
tion (Zgurskaya and Nikaido, 1999b; Tikhonova et al., 2007).
Further studies of MacAB and AcrAB showed that the C-
terminal domains of MFPs are critical for their ability to
stimulate transporters (Ge et al., 2009; Modali and Zgurskaya,
2011). These domains of MFPs interface with periplasmic
domains of transporters and undergo conformational changes
needed for stimulation of transporters. Studies of MacAB-
TolC suggested that MFPs stimulate ABC transporters by sta-
bilizing the closed pre-ATP hydrolysis conformation (Modali
and Zgurskaya, 2011). Assuming conservation of the mecha-
nism, we propose that in the case of RND transporters, MFPs
stabilize the binding-to-extrusion transition that precedes the
transmembrane proton transfer (Figure 5).
3. Interaction with OMF is needed for conformational changes
in MFPs. The in vivo proteolysis approach showed that in vivo
conformational changes in MFPs occur only in the presence
of TolC (Ge et al., 2009; Modali and Zgurskaya, 2011). The
TolC-induced conformational changes in MFPs were further
linked to stimulation of activities of transporters by MFPs and
to stabilization of tri-partite complexes in vitro. Taken together
these results support the model that in vivo MFPs exist in
stable complexes with transporters and that association with
OMF triggers the conformational changes in MFPs needed for
stimulation of transporters (Figure 5).
4. Interactions between transporters and OMFs are dynamic.
Current models postulate that OMF association with an MFP-
transporter complex leads to opening of the channel (Weeks
et al., 2010; Janganan et al., 2013). In the docked models of
AcrAB-TolC, TolC is in the open conformation (Symmons
et al., 2009; Du et al., 2014). The dilation of the TolC channel
in the assembled complex is apparently driven by energy-
dependent conformational changes in MFP-transporter com-
plexes (Janganan et al., 2013). The open and closed conformers
of TolC stabilized by mutations can be readily distinguished in
vivo by drug susceptibility, proteolytic and thiol labeling pro-
files (Krishnamoorthy et al., 2013). However, the interactions
with TolC are highly dynamic and the life-time of TolC-
containing complexes is very short (Tikhonova et al., 2009,
2011). Thus, TolC binding to the inner membrane complexes
is transient.
Based on the data described above, we propose that reaction
cycles of transporters are tightly coupled to the assembly of the
trans-envelope complexes. Transporters and MFPs exist in the
inner membrane as inactive complexes (Figure 5). The activa-
tion of complexes is triggered by MFP binding to OMF, which
leads to a conformational change in MFP needed for stimulation
of transporters. The activated MFP-transporter complex engages
an OMF to expel substrates across the outer membrane. The
recruitment of an OMF is likely triggered by binding of effectors
(substrates) to MFP or MFP-transporter complex. This possibil-
ity has been discussed before for the P. aeruginosa MexJK pump
where experimental evidence strongly suggests that the MexJK
complex recruits either OprM orOpmH in a substrate-dependent
matter (Chuanchuen et al., 2005).
NON-TYPICAL DRUG EFFLUX TRANSPORTERS
The discussed above MFP-transporter complexes have a three-
fold symmetry befitting the trimeric architecture of OMF.
However, asymmetric assemblies like RND transporters MdtABC
or TriABC are also broadly represented in bacterial genomes.
The mechanism and the requirement for asymmetry in such
complexes remain unclear.
MdtB and MdtC share only 50% sequence identity with each
other. The expression of both MdtB and MdtC together with
the MFP MdtA leads to a decreased drug susceptibility of E. coli
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to SDS, novobiocin, cloxacillin, and several bile salts (Baranova
and Nikaido, 2002; Nagakubo et al., 2002; Kim et al., 2010;
Kim and Nikaido, 2012). The expression of MdtAB does not
yield a functional transporter, but expression of MdtAC resulted
in partial activity: a drug resistant phenotype against bile salts.
Co-purification experiments and protein fusion studies suggest
that MdtBC associates as a B2C complex (Kim et al., 2010).
Furthermore, there is convincing evidence that MdtB and MdtC
fulfill distinctly different roles for the transporter. Site-directed
mutagenesis studies have shown that a mutation in the proton
relay network of MdtB abolishes functionality of the complex to a
greater extent than corresponding mutations in MdtC (Kim et al.,
2010). On the other hand, mutations in the proposed drug bind-
ing pocket and 3D docking studies on homology models indicate
that substrates bind primarily to MdtC (Kim and Nikaido, 2012).
The proton relay network in MdtB is thus thought to provide the
energy required for a conformational change inMdtC resulting in
removal of substrates (Mima et al., 2009). This arrangement dif-
fers from the current model of drug expulsion in homotrimeric
RND transporters, in which each protomer is functionally iden-
tical. MuxABC-OpmB in P. aeruginosa similarly includes two
RND components in a single operon MuxB and MuxC. In this
system, both peptides are necessary in order to observe drug resis-
tance against a range of antibiotics including novobiocin and
carbenicillin (Mima et al., 2009; Yang et al., 2011).
In some complexes, the asymmetry arises through hetero-
oligomerization of MFPs. TriABC-OpmH from P. aeruginosa
requires two MFPs TriA and TriB that share 36% sequence iden-
tity with each other (Mima et al., 2007). TriABC-OpmH provides
resistance to triclosan with both TriA and TriB required for efflux
(Mima et al., 2007). TriA and TriB presumably form either a
trimer of dimers or a hetero-oligomeric hexamer. Since both
MFPs share relatively little sequence identity and each of them is
required for activity, it is likely that they serve different functions
for the transporter.
Some transporters include a fourth unique component in their
operons. These proteins are typically not required for functional-
ity of the complex, however their presence modifies the activity of
the transporter. The best characterized efflux pumps with a fourth
component are the ABC transporter YknWXYZ from B. subtilis
(see below) (Yamada et al., 2012), MexGHI-OpmD from P. aerug-
inosa (Aendekerk et al., 2002) and CusF-CusBAC from E. coli
(Kim et al., 2011) (Figure 6). In addition, there are small ∼50 aa
long peptides like AcrZ from E. coli that binds to AcrAB-TolC and
modifies its substrate specificity (Hobbs et al., 2012).
MexGHI-OpmD is required for virulence of P. aeruginosa
and its overproduction decreases susceptibilities to norfloxacin,
ethidium bromide, acriflavine, and rhodamine 6G (Aendekerk
et al., 2002, 2005; Sekiya et al., 2003). The complex is thought
to be involved in the translocation of quorum sensing molecules
that upregulate the transcription of virulence factors. MexH,
MexI and OpmD are MFP, RND, and OMF respectively,
whereas MexG is a small 16.2 kDa protein of unknown func-
tion. According to sequence analysis it is proposed to be a
membrane protein comprising four transmembrane α-helices.
MexHI-OpmD is functional without MexG but the latter is
required for full functionality of the complex (Sekiya et al.,
2003). Homologs of MexG exist in other Gram-negative bac-
teria that are also encoded in operons with RND transporters,
suggesting that the requirement for the fourth component is
FIGURE 6 | Four component transporters. (A) ATP type transporter
YknWXYZ from B. subtilis. YknW is thought to associate with the YknXYZ
complex and seems to be essential for the transporter (Yamada et al., 2012).
(B) MexGHI-OpmD is an RND transporter in P. aeruginosa that is involved in
virulence (Aendekerk et al., 2002, 2005). MexG is proposed to be located in
the inner membrane and contributes to the functionality of MexHI-OpmD
(Sekiya et al., 2003). (C) RND transporter CusBAC-CusF from E. coli. CusF is
a metal chaperon that is thought to donate Cu(I) to the MFP CusB (Argüello
et al., 2011; Mealman et al., 2011; Padilla-Benavides et al., 2014). Shapes in
yellow represent the corresponding substrates for each transporter.
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conserved. More work is needed to elucidate the role of MexG
homologs.
The existence of asymmetric and four-component complexes
implies that current models of theMFP-dependent transport may
be incomplete. It is possible that the asymmetry and additional
components split functional roles of subunits and promote one
of the transition states. What step(s) in the transport could be
enhanced by additional subunits? In case of MFPs, this could be
the separation of roles in the stimulation of a transporter and the
recruitment/opening of OMF. In transporters, this could be an
added substrate specificity or a separation of energy transduction
and substrate translocation as suggested for MdtBC (Nagakubo
et al., 2002; Kim et al., 2010). It is also possible that the hetero-
oligomerization of transporters and MFPs as well as additional
components might serve similar roles in the transport cycle such
as modulation of transporter affinities to substrates and/or MFPs
and OMFs. In this way, asymmetry might increase the specificity
of a MFP-transporter complex to an OMF, which in turn could be
a way to control the activity of the transporter.
MFP-DEPENDENT TRANSPORTERS OF GRAM-POSITIVE
BACTERIA
Although MFPs are ubiquitous in efflux complexes that function
in the context of two membranes, these proteins are also present
in Gram-positive bacteria, which typically lack an outer mem-
brane. Overall, the structures of cell envelopes of Gram-positive
bacteria are poorly characterized, and while Gram-positive and
Gram-negative cell envelopes share some characteristics, they are
chemically and compositionally distinct. MFPs are required for
functions of many transporters in Gram-positive bacteria that
are involved in drug resistance, membrane biogenesis, and pro-
tein secretion (Butcher and Helmann, 2006; Yamada et al., 2012;
Freudl, 2013).
Sequence homology and modeling indicate that MFPs from
Gram-positive bacteria share the same general architecture as
Gram-negative MFPs (Figure 3). The conservation of the α-
hairpin region in Gram-positive MFPs is puzzling, as the region is
thought to be the major contributor toward interactions between
the MFP and OMF in Gram-negative transporters. The best char-
acterized complex is B. subtilis YknWXYZ known to provide
resistance against the endogenously-produced toxin SdpC, which
lyses surrounding cells, freeing nutrients and allowing the cell
to delay sporulation (Butcher and Helmann, 2006). YknWXYZ
shows homology to other ABC-type transporters such as MacAB-
TolC of E. coli, and in addition to the MFP YknX, contains the
components YknYZ and YknW (Figure 6). YknY and YknZ are
an ATPase and a permease components of the transporter. YknW
contains four transmembrane domains, and shares homology
with the Yip1 family of proteins which are involved with vesic-
ular transport in yeast. YknW was shown to affect the oligomeric
state of YknX, or possibly YknX and YknYZ interactions (Yamada
et al., 2012). This furthers the idea that theMFP-transporter inter-
face is largely dependent on conformational changes within the
MFP, and that stimulation of these changes can be conferred by
proteins other than the transporter and OMF.
The functions of Gram-positive MFPs in transporter cycles
await further studies. However, activities of Gram-negative MFPs
are not limited to that of engaging an outer membrane channel
and some of such activities could be also characteristic of Gram-
positive MFPs. First, similar to Gram-negative MFPs, YknX and
other Gram-positive MFPs are expected to be conformationally
flexible. A wide range of MFPs movement (Mikolosko et al.,
2006; Vaccaro et al., 2006; Wang et al., 2012) has been proposed
to be important for stimulation of transporter activities, assem-
bly of functional complexes and substrate extrusion. Second,
MFPs of metal-exporting transporters are known to bind their
substrates. The MFP ZneB from the Cupriavidus metallidurans
ZneCAB export complex is known to exhibit structural changes
upon binding its substrate zinc (De Angelis et al., 2010), the MFP
CusB of the efflux complex CusBAC has been shown to bind its
substrate, copper (Su et al., 2009; Delmar et al., 2013), and the
MFP MacA binds a core LPS molecule, a putative substrate (Lu
and Zgurskaya, 2013). It is possible that Gram-positive MFPs also
receive substrates from their cognate transporters and then release
them into the external medium. Finally, MFPs have also been
proposed to stabilize or destabilize certain conformations of the
transporter, moving the complex through the transport process.
Hence, MFPs in Gram-positive cell envelopes, as in the con-
text of Gram-negative cell envelopes, are likely to play an active
role in the transport process. Interestingly, the predicted MFP
of an ABC-type transporter DSY0927 from Desulfitobacterium
hafniense is a fusion of two different MFPs. The N-terminal half
of the protein shows homology to MF-type MFPs and does not
have a coiled-coil domain, whereas the C-terminal half of the pro-
tein shares more characteristics of an RND-type MFP (Zgurskaya
et al., 2009). This finding further suggests that similar to Gram-
negatives, Gram-positive MFPs likely function as dimers, with
each MFP molecule attaining a specific role in the transport
cycle.
CONCLUSIONS
The proposed model together with recent structural and func-
tional advances provides a fairly detailed understanding of the
mechanism of drug efflux across the two membrane envelopes
of Gram-negative bacteria. Allosteric inhibitors that target spe-
cific conformations of MFPs and prevent these proteins from
binding to OMF and activation of transporters could be effec-
tive in potentiation of activities of antibiotics. Further studies are
needed: (i) to identify MFP-transporter and MFP-OMF molec-
ular interfaces that are critical for activation of efflux and (ii)
to characterize conformational transitions in all components of
the complexes leading to efflux across the outer membrane. Non-
typical transporters could be powerful tools in understanding
how the trans-envelope efflux is achieved. There is a significant
gap in knowledge about functions of MFPs in the context of
Gram-positive cell envelopes.
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